- Home
- OTLK vs RNAC Comparison
OTLK vs RNAC Comparison
Compare OTLK & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | RNAC |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 218.4M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | OTLK | RNAC |
|---|---|---|
| Price | $0.41 | $6.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.03 | ★ $33.67 |
| AVG Volume (30 Days) | ★ 3.0M | 119.0K |
| Earning Date | 12-18-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,146,123.00 | $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,355.64 | $274.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $5.60 |
| 52 Week High | $2.54 | $11.00 |
Technical Indicators
Market Signals| Indicator | OTLK | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 41.88 |
| Support Level | $0.39 | $5.90 |
| Resistance Level | $0.46 | $6.60 |
| Average True Range (ATR) | 0.04 | 0.52 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 1.52 | 10.59 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.